Bristol Myers Squibb’s CAR-T therapy Breyanzi (lisocabtagene maraleucel) for treating large B-cell lymphoma is among several new drugs to be recommended for pan-EU approval this week.
If approved, Breyanzi will become the third CAR-T therapy on the European LBCL market. It is intended for treating adults...








